Endo Pharmaceuticals has launched Valstar (valrubicin), an anthracycline derivative, for the treatment of Bacille Calmette-Guerin (BCG)-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality. Valstar, a sterile solution of valrubicin for intravesical instillation, is placed directly into the bladder through a catheter and is administered once weekly.

Valstar was voluntarily withdrawn from the U.S. market in 2002 due to a formulation issue with an inactive component. The reintroduction of Valstar follows the FDA’s February 27, 2009 approval of a modified formulation of Valstar.

For more information call (800) 462-ENDO or visit www.endo.com.